Scarica l'app Stockscreener
20.90
0.05%
0.010
Dopo l'orario di chiusura:
20.90
Precedente Chiudi:
$20.89
Aprire:
$21.33
Volume 24 ore:
1.18M
Relative Volume:
0.96
Capitalizzazione di mercato:
$2.37B
Reddito:
$4.02M
Utile/perdita netta:
$-224.59M
Rapporto P/E:
-8.7834
EPS:
-2.3795
Flusso di cassa netto:
$-205.52M
1 W Prestazione:
-2.38%
1M Prestazione:
-23.53%
6M Prestazione:
-4.30%
1 anno Prestazione:
+82.21%
Intervallo 1D:
$20.82
$21.46
Intervallo di 1 settimana:
$20.71
$22.55
Portata 52W:
$11.55
$30.06
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.90 | 2.43B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-28 | Iniziato | Barclays | Overweight |
| 2026-02-12 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
IMNM Initiated Coverage by Stifel -- Rated Hold with PT at $24.0 - GuruFocus
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues - Yahoo Finance
Immunome gains FDA IND clearance for IM‑1340 solid tumour study - Mugglehead Investment Magazine
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com - Investing.com Nigeria
Immunome, Inc. (IMNM) stock price, news, quote and history - uk.finance.yahoo.com
Immunome (IMNM) Gains FDA IND Clearance for IM-1340 Targeting Ad - GuruFocus
Immunome receives FDA clearance for IM-1340 solid tumor trial - Investing.com
Immunome receives FDA clearance for IM-1340 solid tumor trial By Investing.com - Investing.com South Africa
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Business Wire
(IMNM) Risk Channels and Responsive Allocation - Stock Traders Daily
A. G. P. Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $32 - Moomoo
IMNM Initiates Coverage On Alliance Global Partners -- Rating Se - GuruFocus
Immunome Inc. (IMNM) Edges Higher to $23.97 as Traders Eye $25.17 ResistanceQuality ETF - siam.in
Immunome stock gains as analyst targets highlight upside potential - AD HOC NEWS
Immunome Stock Price Forecast. Should You Buy IMNM? - StockInvest.us
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Immunome CSO Higgins Jack Executes 18,000 Options at $1.35, Sells and Gifts Shares (NASDAQ: IMNM) - Kalkine Media
Immunome Inc. (IMNM) Edges Up 2.51% to $24.55 as Buyers Hold Above Key SupportPCR Spike - careplusvn.com
Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily
Planned sale of 13,200 Immunome (NASDAQ: IMNM) shares disclosed in Rule 144 notice - stocktitan.net
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
IMNM Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesEarnings Miss Alert - dars.gov.et
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM - TradingView
Immunome Inc (NASDAQ: IMNM) Share Price, IMNM Stock News, IMNM Share Price & Updates - kalkine.ca
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Immunome (NASDAQ:IMNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified? - Sahm
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateCommon Gap - siam.in
Immunome (IMNM) Results Review: EPS Clears the Reported Estimate for the Current Session; Closing Move - dars.gov.et
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - Sahm
Immunome (IMNM) Financial Update: EPS Beats Its Estimate in the Latest Session; Investor Response: Shares Close 1.57% Higher for the Current SessionProduct Revenue Analysis - careplusvn.com
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
IMNM|Immunome Inc|Price:28.520|Chg%:+0.440 - TradingKey
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed - simplywall.st
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immunome (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.95% Stock GainRevenue Miss Report - vinanet.vn
IMNM Q1 2026 Earnings: Narrower Net Loss Beats on Cost ControlPerformance Review - vinanet.vn
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunome Inc Azioni (IMNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Sep 11 '26 |
Sale |
25.32 |
13,200 |
334,224 |
65,050 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):